26 February 2026
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business
Share:The acquisition further enhances LGC’s ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence.
London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC’s reference materials offering and strengthens its commercial reach across North America.
The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC’s ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets.
Bruno Rossi, EVP & General Manager, LGC Standards, said: “The ChromaDex standards portfolio further enhances LGC’s ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC’s position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains.”
For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains.
Rob Fried, CEO of Niagen Bioscience, remarked, “This transaction reflects our disciplined focus on what we do best—advancing NAD+ science and delivering clinically proven, patented Niagen® solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders.”
The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC’s commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World.
-ends-
About LGC
LGC is a global leader in life sciences, diagnostics, and analytical solutions. We work with partners around the world to address some of society’s most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health.
Our science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, we provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions.
With operations in 14 countries and more than 180 years of scientific expertise, our work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, our solutions are trusted by customers in more than 170 countries.
For further information please contact:
Customer contact:
Richard Pembrey
Sales Director, LGC Standards
+1 603 851 2834
Media contact:
Magda Bartoszewicz
Director Corporate Brand and Communications, LGC Group
+44 7408 850 514